3:37 PM
 | 
Dec 07, 2017
 |  BC Extra  |  Clinical News

Spark reports bleeding rate data for hemophilia B therapy

Data published in the New England Journal of Medicine from a Phase I/II trial in 10 hemophilia B patients showed that a single dose of gene therapy candidate SPK-9001 from Spark Therapeutics Inc. (NASDAQ:ONCE) and Pfizer Inc. (NYSE:PFE) reduced annualized bleeding...

Read the full 187 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >